JP2020503273A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503273A5 JP2020503273A5 JP2019529206A JP2019529206A JP2020503273A5 JP 2020503273 A5 JP2020503273 A5 JP 2020503273A5 JP 2019529206 A JP2019529206 A JP 2019529206A JP 2019529206 A JP2019529206 A JP 2019529206A JP 2020503273 A5 JP2020503273 A5 JP 2020503273A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- antibody
- human
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 78
- 102000049823 human TIGIT Human genes 0.000 claims description 78
- 238000000034 method Methods 0.000 claims description 76
- 206010028980 Neoplasm Diseases 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 22
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 230000004614 tumor growth Effects 0.000 claims description 17
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 14
- 229940123751 PD-L1 antagonist Drugs 0.000 claims description 14
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 12
- 206010038038 rectal cancer Diseases 0.000 claims description 12
- 201000001275 rectum cancer Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000000112 colonic effect Effects 0.000 claims description 10
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 9
- 108010048507 poliovirus receptor Proteins 0.000 claims description 9
- 108091092878 Microsatellite Proteins 0.000 claims description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 6
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 5
- 206010061424 Anal cancer Diseases 0.000 claims description 4
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000011165 anus cancer Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000006974 gastroesophageal cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 6
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 229960005386 ipilimumab Drugs 0.000 claims 6
- 229960002621 pembrolizumab Drugs 0.000 claims 6
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 4
- 102000048776 human CD274 Human genes 0.000 claims 4
- 102000048362 human PDCD1 Human genes 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 229960003852 atezolizumab Drugs 0.000 claims 3
- 229950002916 avelumab Drugs 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 229960005395 cetuximab Drugs 0.000 claims 3
- 229950009791 durvalumab Drugs 0.000 claims 3
- 230000002357 endometrial effect Effects 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 229960003301 nivolumab Drugs 0.000 claims 3
- 229960001972 panitumumab Drugs 0.000 claims 3
- 229960002087 pertuzumab Drugs 0.000 claims 3
- 229950010968 romosozumab Drugs 0.000 claims 3
- 229960000575 trastuzumab Drugs 0.000 claims 3
- 230000005751 tumor progression Effects 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 206010014733 Endometrial cancer Diseases 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 208000032818 Microsatellite Instability Diseases 0.000 description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022103151A JP2022130561A (ja) | 2016-11-30 | 2022-06-28 | Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427903P | 2016-11-30 | 2016-11-30 | |
| US62/427,903 | 2016-11-30 | ||
| US201762479609P | 2017-03-31 | 2017-03-31 | |
| US62/479,609 | 2017-03-31 | ||
| PCT/US2017/063918 WO2018102536A1 (en) | 2016-11-30 | 2017-11-30 | Methods for treatment of cancer comprising tigit-binding agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022103151A Division JP2022130561A (ja) | 2016-11-30 | 2022-06-28 | Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503273A JP2020503273A (ja) | 2020-01-30 |
| JP2020503273A5 true JP2020503273A5 (https=) | 2021-10-14 |
| JP7126269B2 JP7126269B2 (ja) | 2022-08-26 |
Family
ID=62241934
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529206A Active JP7126269B2 (ja) | 2016-11-30 | 2017-11-30 | Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法 |
| JP2022103151A Pending JP2022130561A (ja) | 2016-11-30 | 2022-06-28 | Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022103151A Pending JP2022130561A (ja) | 2016-11-30 | 2022-06-28 | Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11230596B2 (https=) |
| EP (1) | EP3548071A4 (https=) |
| JP (2) | JP7126269B2 (https=) |
| KR (1) | KR102461228B1 (https=) |
| CN (1) | CN110662552A (https=) |
| AU (1) | AU2017368155B2 (https=) |
| BR (1) | BR112019010943A8 (https=) |
| CA (1) | CA3044664C (https=) |
| IL (1) | IL266847B2 (https=) |
| MX (1) | MX2019006072A (https=) |
| NZ (1) | NZ753515A (https=) |
| RU (1) | RU2765410C2 (https=) |
| WO (1) | WO2018102536A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3208612B1 (en) | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| CN110662552A (zh) * | 2016-11-30 | 2020-01-07 | 昂科梅德制药有限公司 | 包含tigit结合剂的癌症治疗方法 |
| RS64576B1 (sr) | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antitela i postupci njihove primene |
| WO2018229163A1 (en) * | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| CN108948182A (zh) * | 2018-07-25 | 2018-12-07 | 中国人民解放军第四军医大学 | Tigit-ecd重组蛋白抗同种异体免疫排斥反应的应用 |
| TWI728400B (zh) | 2018-07-26 | 2021-05-21 | 美商美國禮來大藥廠 | Cd226促效劑抗體 |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| US20220241375A1 (en) | 2019-05-20 | 2022-08-04 | Cytune Pharma | Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases |
| KR102332847B1 (ko) * | 2019-06-13 | 2021-12-01 | 주식회사 녹십자 | Tigit에 대한 항체 및 이의 용도 |
| CN112625130B (zh) * | 2019-09-24 | 2023-08-29 | 财团法人工业技术研究院 | 抗-tigit抗体及使用之方法 |
| US20220340660A1 (en) * | 2019-10-01 | 2022-10-27 | Merck Sharp & Dohme Corp. | Biomarkers for anti-tigit antibody treatment |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| CA3176497A1 (en) | 2020-05-07 | 2021-11-11 | Fatima MECHTA-GRIGORIOU | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| CN115916348A (zh) | 2020-06-18 | 2023-04-04 | 基因泰克公司 | 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| MX2023004880A (es) | 2020-10-26 | 2023-05-11 | Cytune Pharma | AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA. |
| EP4232069A1 (en) | 2020-10-26 | 2023-08-30 | Cytune Pharma | Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| EP4255464A4 (en) * | 2020-12-03 | 2025-02-26 | Shattuck Labs, Inc. | METHODS OF TREATING CANCER USING CHIMERIC PROTEINS FORMED FROM TIGIT AND LIGHT |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AU2022253351A1 (en) | 2021-04-09 | 2023-10-12 | Boehringer Ingelheim International Gmbh | New scaffold for bifunctional molecules with improved properties |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| CN117597355A (zh) | 2021-06-23 | 2024-02-23 | 赛腾制药 | 白细胞介素15变体 |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| US20240350589A1 (en) | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| CA3256561A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and their uses |
| WO2023234743A1 (ko) * | 2022-06-03 | 2023-12-07 | (주)지아이이노베이션 | 항-tigit 항체를 포함하는 이중 특이적 항체 및 이의 용도 |
| EP4537107A2 (en) | 2022-06-07 | 2025-04-16 | Genentech, Inc. | Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| CN121358499A (zh) | 2023-03-30 | 2026-01-16 | Ose免疫疗法 | 靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途 |
| AU2024254671A1 (en) | 2023-03-30 | 2025-10-02 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025188136A1 (en) * | 2024-03-04 | 2025-09-12 | Abl Bio, Inc. | Anti-tigit/anti-4-1bb bispecific antibodies and uses thereof |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7282570B2 (en) | 1999-04-20 | 2007-10-16 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20080050809A1 (en) | 1999-09-28 | 2008-02-28 | Alejandro Abuin | Novel human kinases and polynucleotides encoding the same |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| CU23007A1 (es) | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
| WO2003068943A2 (en) | 2002-02-13 | 2003-08-21 | Incyte Corporation | Secreted proteins |
| EP2388265A1 (en) | 2002-02-22 | 2011-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| US20040121370A1 (en) | 2002-09-11 | 2004-06-24 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| US7550800B2 (en) | 2003-06-06 | 2009-06-23 | Chih-Hsin Wang | Method and apparatus transporting charges in semiconductor device and semiconductor memory device |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| EP3214095B1 (en) | 2005-05-12 | 2019-12-11 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US20090142346A1 (en) | 2005-10-07 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Preventive/Remedy for Cancer |
| JP5129149B2 (ja) | 2005-10-31 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を処置および診断するための組成物および方法 |
| EA018260B1 (ru) | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
| CA2666249A1 (en) | 2006-10-06 | 2008-04-17 | Takeda Pharmaceutical Company Limited | Agent for preventing/treating cancer |
| DE102008028564A1 (de) | 2007-07-03 | 2009-01-08 | Luk Lamellen Und Kupplungsbau Beteiligungs Kg | Hydrauliksystem zum Erzeugen eines Vorsteuerdruckes zum Ansteuern einer Getriebekomponente |
| KR20190140090A (ko) | 2007-07-09 | 2019-12-18 | 제넨테크, 인크. | 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지 |
| EP3208612B1 (en) | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| US8551715B2 (en) | 2010-02-12 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for identifying and isolating cells expressing a polypeptide |
| CA3083324A1 (en) | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| WO2012113813A1 (en) | 2011-02-23 | 2012-08-30 | F. Hoffmann-La Roche Ag | Antibodies against human il33r and uses thereof |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| CN104968364A (zh) | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | 强化免疫调变性Fc融合蛋白的抗癌活性 |
| HK1210964A1 (en) | 2012-12-04 | 2016-05-13 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| CN103073644B (zh) | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 |
| US9062104B2 (en) | 2013-03-14 | 2015-06-23 | Alderbio Holdings Llc | Therapeutic use of antibodies to HGF |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| CA2916681A1 (en) | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| AU2015228372B2 (en) | 2014-03-12 | 2018-05-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| WO2015143343A2 (en) | 2014-03-21 | 2015-09-24 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
| SG11201700258VA (en) * | 2014-07-16 | 2017-02-27 | Genentech Inc | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
| TWI750110B (zh) * | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| AU2015305754B2 (en) | 2014-08-19 | 2018-10-25 | Merck Sharp & Dohme Llc | Anti-tigit antibodies |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| AU2015327868A1 (en) | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| KR20170072343A (ko) | 2014-11-06 | 2017-06-26 | 제넨테크, 인크. | Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법 |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| CN107207594B (zh) | 2014-12-23 | 2019-05-07 | 百时美施贵宝公司 | 针对tigit的抗体 |
| JP2018503373A (ja) | 2014-12-30 | 2018-02-08 | ジェネンテック， インコーポレイテッド | がんの予後診断及び治療のための方法及び組成物 |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| EP3334757A4 (en) | 2015-08-14 | 2019-04-03 | Merck Sharp & Dohme Corp. | ANTI-Tigit ANTIBODY |
| CN108137691B (zh) | 2015-09-02 | 2021-10-19 | 耶路撒冷希伯来大学伊萨姆研究发展有限公司 | 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体 |
| EP3349792A1 (en) | 2015-09-14 | 2018-07-25 | Compass Therapeutics LLC | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf- |
| CA2994858C (en) | 2015-09-25 | 2024-01-23 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
| PL3356413T3 (pl) | 2015-10-01 | 2022-04-19 | Potenza Therapeutics, Inc. | Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania |
| WO2017152088A1 (en) | 2016-03-04 | 2017-09-08 | JN Biosciences, LLC | Antibodies to tigit |
| US10731128B2 (en) * | 2016-11-22 | 2020-08-04 | Alloplex Biotherapeutics, Inc. | Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells |
| CN110662552A (zh) * | 2016-11-30 | 2020-01-07 | 昂科梅德制药有限公司 | 包含tigit结合剂的癌症治疗方法 |
| EP3589313A4 (en) | 2017-02-28 | 2021-05-19 | Seagen Inc. | ANTI-TIGITE ANTIBODY |
| US20200024351A1 (en) * | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
| RS64576B1 (sr) | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antitela i postupci njihove primene |
| KR20200041834A (ko) * | 2017-06-01 | 2020-04-22 | 젠코어 인코포레이티드 | Cd123 및 cd3에 결합하는 이중특이성 항체 |
| CN110799213A (zh) * | 2017-06-01 | 2020-02-14 | 康姆普根有限公司 | 三联组合抗体疗法 |
| GB201709808D0 (en) * | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019023504A1 (en) | 2017-07-27 | 2019-01-31 | Iteos Therapeutics Sa | ANTI-TIGIT ANTIBODIES |
| EP3697435A1 (en) * | 2017-10-20 | 2020-08-26 | Fred Hutchinson Cancer Research Center | Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression |
| CA3097625A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| AT521173B1 (de) | 2018-06-27 | 2019-11-15 | Trumpf Maschinen Austria Gmbh & Co Kg | Biegewerkzeug mit Distanzelement |
-
2017
- 2017-11-30 CN CN201780074119.5A patent/CN110662552A/zh active Pending
- 2017-11-30 BR BR112019010943A patent/BR112019010943A8/pt unknown
- 2017-11-30 RU RU2019115428A patent/RU2765410C2/ru active
- 2017-11-30 US US16/464,820 patent/US11230596B2/en active Active
- 2017-11-30 MX MX2019006072A patent/MX2019006072A/es unknown
- 2017-11-30 AU AU2017368155A patent/AU2017368155B2/en active Active
- 2017-11-30 KR KR1020197017345A patent/KR102461228B1/ko active Active
- 2017-11-30 JP JP2019529206A patent/JP7126269B2/ja active Active
- 2017-11-30 CA CA3044664A patent/CA3044664C/en active Active
- 2017-11-30 NZ NZ753515A patent/NZ753515A/en not_active IP Right Cessation
- 2017-11-30 EP EP17876358.7A patent/EP3548071A4/en not_active Withdrawn
- 2017-11-30 WO PCT/US2017/063918 patent/WO2018102536A1/en not_active Ceased
-
2019
- 2019-05-23 IL IL266847A patent/IL266847B2/en unknown
-
2020
- 2020-12-11 US US17/119,883 patent/US11136384B2/en active Active
-
2021
- 2021-12-09 US US17/547,178 patent/US20220340653A1/en not_active Abandoned
-
2022
- 2022-06-28 JP JP2022103151A patent/JP2022130561A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503273A5 (https=) | ||
| RU2019115428A (ru) | Способы лечения рака, включающие связывающие tigit агенты | |
| US20230115328A1 (en) | Anti-B7-H1 and Anti-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer | |
| AU2020276242B2 (en) | Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer | |
| JP6877147B2 (ja) | 放射線療法と併用されるｐｄ−１およびｐｄ−ｌ１に対する拮抗薬を用いたがんの治療法 | |
| JP2023126946A (ja) | 抗ｌａｇ－３抗体、ｐｄ－１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| JP6805428B2 (ja) | Ｃｅａｃａｍ１に対するヒト化抗体 | |
| JP2018503365A5 (https=) | ||
| JPWO2020232019A5 (https=) | ||
| JP2023011902A (ja) | Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 | |
| JPWO2019143607A5 (https=) | ||
| JP2024519449A (ja) | がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用 | |
| KR20230056761A (ko) | Pd-1 저해제의 투여에 의한 암 치료 방법 | |
| WO2025058453A1 (en) | Methods of treating cancer by administering anti-pd-l1/anti-4-1bb bispecific antibodies | |
| Brogna et al. | Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges: MR Brogna et al. | |
| KR20230159833A (ko) | Pd-1 저해제의 투여에 의한 폐암 치료 방법 | |
| JPWO2022270523A5 (https=) | ||
| EA049485B1 (ru) | Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака | |
| JPWO2023057534A5 (https=) | ||
| JPWO2023078386A5 (https=) |